Aetna this week up to date its protection coverage to incorporate noninvasive prenatal testing for all pregnancies.
In line with Aetna’s up to date coverage, the Hartford, Connecticut-based insurer now considers NIPT utilizing measurement of cell-free fetal nucleic acids in maternal blood to be medically obligatory for screening for fetal aneuploidy in all pregnant ladies.
The transfer comes at a time when quite a few payors, together with UnitedHealthcare and Humana, have begun providing protection of NIPT for average-risk pregnancies. This summer time, the American School of Obstetricians and Gynecologists issued new tips recommending prenatal aneuploidy screening for all pregnant ladies no matter their age or different threat components.
A number of corporations provide NIPT for average-risk pregnancies however Natera is broadly seen as the largest beneficiary as extra payors now present protection for that market.
In line with San Carlos, California-based Natera, which gives the Panorama SNP-based prenatal blood take a look at for the early detection of genetic issues, roughly 90% of all commercially coated lives within the U.S. now have average-risk NIPT protection.
“With the choices made this week, all 20 of the most important industrial payors now cowl NIPT, impartial of prior threat,” Ramesh Hariharan, basic supervisor of Natera’s ladies’s well being enterprise, mentioned in a press release. “With our distinctive SNP-based NIPT, we may have a good better alternative to make a constructive impression on prenatal care.”
This story first appeared in our sister publication, Genomeweb.